Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1986 Aug;83(15):5620–5624. doi: 10.1073/pnas.83.15.5620

Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.

S Torsteinsdottir, M G Masucci, B Ehlin-Henriksson, C Brautbar, H Ben Bassat, G Klein, E Klein
PMCID: PMC386340  PMID: 3016710

Abstract

Sets of Burkitt lymphoma lines and Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) derived from the same individuals were compared for sensitivity to cytotoxic T-lymphocyte (CTL) clones. Major histocompatibility complex class I antigen-restricted CTL clones were generated by stimulating the lymphocytes of an EBV-seropositive individual with the autologous LCL. One clone (BK-20) lysed the autologous and allogeneic HLA-A11-expressing LCLs but not mitogen-induced B lymphoblasts. Thus the clone was selectively cytotoxic for LCLs. Allospecific CTL clones directed against the HLA-A11 antigen were generated from an EBV-seronegative individual. One clone (WP-36) was selectively cytotoxic for the appropriate allospecific LCL, whereas another clone (WP-21) lysed also T and B lymphoblasts. None of the four Burkitt lymphoma lines established in parallel with the CTL-sensitive LCLs were lysed. Two of the Burkitt lymphoma lines were EBV-negative, and EBV-positive sublines were derived from these by in vitro infection. One but not the other of the two convertants became sensitive to all three types of CTL clones. The CTL-sensitive converted line had also acquired some LCL characteristics: increased cell size, aggregation, and a shift in several of the B-cell-specific surface markers. The CTL-resistant convertant expressed EBV antigens but showed no phenotypic change. These findings suggest that the cellular phenotype plays a decisive role in the sensitivity of B-cell-derived lines to the lytic effect of LCL-selective autologous and allogeneic CTLs.

Full text

PDF
5620

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson M., Klein G., Zeigler J. L., Henle W. Association of Epstein-Barr viral genomes with American Burkitt lymphoma. Nature. 1976 Mar 25;260(5549):357–359. doi: 10.1038/260357a0. [DOI] [PubMed] [Google Scholar]
  2. Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res. 1986;47:189–234. doi: 10.1016/s0065-230x(08)60200-6. [DOI] [PubMed] [Google Scholar]
  3. Favrot M. C., Philip I., Philip T., Portoukalian J., Doré J. F., Lenoir G. M. Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin. J Natl Cancer Inst. 1984 Oct;73(4):841–847. [PubMed] [Google Scholar]
  4. Gaston J. S., Rickinson A. B., Epstein M. A. Epstein-Barr virus-specific cytotoxic T lymphocytes as probes of HLA polymorphism. Heterogeneity of T cell-restricting determinants associated with the serologically defined HLA-A2 antigen. J Exp Med. 1983 Aug 1;158(2):280–293. doi: 10.1084/jem.158.2.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Giovanella B., Nilsson K., Zech L., Yim O., Klein G., Stehlin J. S. Growth of diploid, Epstein-Barr virus-carrying human lymphoblastoid cell lines heterotransplanted into nude mice under immunologically privileged conditions. Int J Cancer. 1979 Jul 15;24(1):103–113. doi: 10.1002/ijc.2910240118. [DOI] [PubMed] [Google Scholar]
  6. Klein G., Ehlin-Henriksson B., Schlossman S. F. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains. J Immunol. 1983 Apr;130(4):1985–1989. [PubMed] [Google Scholar]
  7. Klein G., Manneborg-Sandlund A., Ehlin-Henriksson B., Godal T., Wiels J., Tursz T. Expression of the BLA antigen, defined by the monoclonal 38.13 antibody, on Burkitt lymphoma lines, lymphoblastoid cell lines, their hybrids and other B-cell lymphomas and leukemias. Int J Cancer. 1983 May 15;31(5):535–542. doi: 10.1002/ijc.2910310503. [DOI] [PubMed] [Google Scholar]
  8. Klein G. Studies on the Epstein-Barr Virus genome and the EBV-determined nuclear antigen in human malignant disease. Cold Spring Harb Symp Quant Biol. 1975;39(Pt 2):783–790. doi: 10.1101/sqb.1974.039.01.090. [DOI] [PubMed] [Google Scholar]
  9. Klein G. The role of gene dosage and genetic transpositions in carcinogenesis. Nature. 1981 Nov 26;294(5839):313–318. doi: 10.1038/294313a0. [DOI] [PubMed] [Google Scholar]
  10. Levine P. H., Kamaraju L. S., Connelly R. R., Berard C. W., Dorfman R. F., Magrath I., Easton J. M. The American Burkitt's Lymphoma Registry: eight years' experience. Cancer. 1982 Mar 1;49(5):1016–1022. doi: 10.1002/1097-0142(19820301)49:5<1016::aid-cncr2820490527>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  11. McMichael A. J., Ting A., Zweerink H. J., Askonas B. A. HLA restriction of cell-mediated lysis of influenza virus-infected human cells. Nature. 1977 Dec 8;270(5637):524–526. doi: 10.1038/270524a0. [DOI] [PubMed] [Google Scholar]
  12. Moss D. J., Wallace L. E., Rickinson A. B., Epstein M. A. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro. Eur J Immunol. 1981 Sep;11(9):686–693. doi: 10.1002/eji.1830110904. [DOI] [PubMed] [Google Scholar]
  13. Nadler L. M., Stashenko P., Hardy R., van Agthoven A., Terhorst C., Schlossman S. F. Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol. 1981 May;126(5):1941–1947. [PubMed] [Google Scholar]
  14. Nilsson K., Giovanella B. C., Stehlin J. S., Klein G. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer. 1977 Mar 15;19(3):337–344. doi: 10.1002/ijc.2910190309. [DOI] [PubMed] [Google Scholar]
  15. Nilsson K., Klein G. Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. Adv Cancer Res. 1982;37:319–380. doi: 10.1016/s0065-230x(08)60886-6. [DOI] [PubMed] [Google Scholar]
  16. Philip I., Philip T., Favrot M., Vuillaume M., Fontaniere B., Chamard D., Lenoir G. M. Establishment of lymphomatous cell lines from bone marrow samples from patients with Burkitt's lymphoma. J Natl Cancer Inst. 1984 Oct;73(4):835–840. [PubMed] [Google Scholar]
  17. Rabin H., Hopkins R. F., 3rd, Ruscetti F. W., Neubauer R. H., Brown R. L., Kawakami T. G. Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J Immunol. 1981 Nov;127(5):1852–1856. [PubMed] [Google Scholar]
  18. Rickinson A. B., Moss D. J., Wallace L. E., Rowe M., Misko I. S., Epstein M. A., Pope J. H. Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res. 1981 Nov;41(11 Pt 1):4216–4221. [PubMed] [Google Scholar]
  19. Ritz J., Pesando J. M., Notis-McConarty J., Lazarus H., Schlossman S. F. A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature. 1980 Feb 7;283(5747):583–585. doi: 10.1038/283583a0. [DOI] [PubMed] [Google Scholar]
  20. Rooney C. M., Rickinson A. B., Moss D. J., Lenoir G. M., Epstein M. A. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro. Int J Cancer. 1984 Sep 15;34(3):339–348. doi: 10.1002/ijc.2910340310. [DOI] [PubMed] [Google Scholar]
  21. Rooney C. M., Rowe M., Wallace L. E., Rickinson A. B. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature. 1985 Oct 17;317(6038):629–631. doi: 10.1038/317629a0. [DOI] [PubMed] [Google Scholar]
  22. Rowe M., Hildreth J. E., Rickinson A. B., Epstein M. A. Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity. Int J Cancer. 1982 Apr 15;29(4):373–381. doi: 10.1002/ijc.2910290403. [DOI] [PubMed] [Google Scholar]
  23. Rowe M., Rooney C. M., Edwards C. F., Lenoir G. M., Rickinson A. B. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer. 1986 Mar 15;37(3):367–373. doi: 10.1002/ijc.2910370307. [DOI] [PubMed] [Google Scholar]
  24. Rowe M., Rooney C. M., Rickinson A. B., Lenoir G. M., Rupani H., Moss D. J., Stein H., Epstein M. A. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer. 1985 Apr 15;35(4):435–441. doi: 10.1002/ijc.2910350404. [DOI] [PubMed] [Google Scholar]
  25. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622–1626. doi: 10.1073/pnas.72.4.1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Terasaki P. I., Bernoco D., Park M. S., Ozturk G., Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol. 1978 Feb;69(2):103–120. doi: 10.1093/ajcp/69.2.103. [DOI] [PubMed] [Google Scholar]
  27. Torsteinsdottir S., Masucci M. G., Brautbar C., Lenoir G., Klein G., Klein E. Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones. Cell Immunol. 1986 Apr 1;98(2):453–466. doi: 10.1016/0008-8749(86)90304-7. [DOI] [PubMed] [Google Scholar]
  28. Torsteinsdottir S., Masucci M. G., Lenoir G., Klein G., Klein E. Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers. Cell Immunol. 1984 Jul;86(2):278–286. doi: 10.1016/0008-8749(84)90382-4. [DOI] [PubMed] [Google Scholar]
  29. Wallace L. E., Rickinson A. B., Rowe M., Epstein M. A. Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature. 1982 Jun 3;297(5865):413–415. doi: 10.1038/297413a0. [DOI] [PubMed] [Google Scholar]
  30. Ware C. F., Krangel M. S., Pious D., Burakoff S. J., Strominger J. L. Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line. J Immunol. 1983 Sep;131(3):1312–1317. [PubMed] [Google Scholar]
  31. Wiels J., Fellous M., Tursz T. Monoclonal antibody against a Burkitt lymphoma-associated antigen. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6485–6488. doi: 10.1073/pnas.78.10.6485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Zech L., Haglund U., Nilsson K., Klein G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 1976 Jan 15;17(1):47–56. doi: 10.1002/ijc.2910170108. [DOI] [PubMed] [Google Scholar]
  33. Zinkernagel R. M., Doherty P. C. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature. 1974 Oct 11;251(5475):547–548. doi: 10.1038/251547a0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES